The nuclear receptor REV-ERBα modulates Th17 cell-mediated autoimmune disease.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 31455731.
- Also identified by DOI 10.1073/pnas.1907563116 and PMC identifier 6744854.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
T helper 17 (Th17) cells produce interleukin-17 (IL-17) cytokines and drive inflammatory responses in autoimmune diseases such as multiple sclerosis. The differentiation of Th17 cells is dependent on the retinoic acid receptor-related orphan nuclear receptor RORγt. Here, we identify REV-ERBα (encoded by <i>Nr1d1</i>), a member of the nuclear hormone receptor family, as a transcriptional repressor that antagonizes RORγt function in Th17 cells. REV-ERBα binds to ROR response elements (RORE) in Th17 cells and inhibits the expression of RORγt-dependent genes including <i>Il17a</i> and <i>Il17f</i> Furthermore, elevated REV-ERBα expression or treatment with a synthetic REV-ERB agonist significantly delays the onset and impedes the progression of experimental autoimmune encephalomyelitis (EAE). These results suggest that modulating REV-ERBα activity may be used to manipulate Th17 cells in autoimmune diseases.
Medical subject headings
- Encephalomyelitis, Autoimmune, Experimental
- Multiple Sclerosis
- Nuclear Receptor Subfamily 1, Group D, Member 1
- Nuclear Receptor Subfamily 1, Group F, Member 3
- Th17 Cells